Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success

Approval For PSVT Pending At The US FDA

The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.

Atrial fibrillation medical condition and normal or abnormal heart rate rhythm as a cardiac disorder — Etripamil rapidly slowed ventricular rates in atrial fibrillation patients • Source: Shutterstock

Milestone Pharmaceuticals, Inc.’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment for paroxysmal supraventricular tachycardia (PSVT). Now, the company plans to initiate a Phase III trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) after the drug was similarly effective at lowering heart rate in the Phase II ReVeRA study of AFib-RVR patients.

Key Takeaways

Milestone reported positive Phase II results for its calcium channel blocker etripamil, administered via nasal spray, as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Montreal and Charlotte, NC-based Milestone submitted a new drug application for etripamil in the treatment of PSVT to the US...